1. Early lenalidomide treatment for low and intermediate-1 International Prognostic Scoring System risk myelodysplastic syndromes with del(5q) before transfusion dependence
- Author
-
Grazia Sanpaolo, Agostino Cortelezzi, Ulrich Germing, Francesca Ronco, Antonio Volpe, Michael Lauseker, Irene Santacaterina, Enrico Balleari, Antonella Poloni, Giuseppe A. Palumbo, Maria Antonietta Aloe Spiriti, Andrea Kündgen, Caterina Alati, Maria Grazia D'Errigo, Roberto Latagliata, Esther Oliva, and Alessandra Ricco
- Subjects
Cancer Research ,Pediatrics ,pair 5 ,Gastroenterology ,Quality of life ,middle aged ,humans ,Original Research ,Aged, 80 and over ,education.field_of_study ,adult ,chromosome deletion ,5q deletion syndrome ,immunologic factors ,anemia ,myelodysplastic syndromes ,follow-up studies ,aged ,female ,Oncology ,International Prognostic Scoring System ,Chromosomes, Human, Pair 5 ,medicine.drug ,chromosomes ,medicine.medical_specialty ,Anemia ,lenalidomide ,Population ,nuclear medicine and imaging ,quality of life ,Radiology, Nuclear Medicine and Imaging ,male ,thalidomide ,Internal medicine ,medicine ,Radiology, Nuclear Medicine and imaging ,human ,aged 80 and over ,biomarkers ,prognosis ,treatment outcome ,chromosomes, human, pair 5 ,oncology ,radiology, nuclear medicine and imaging ,cancer research ,education ,Lenalidomide ,business.industry ,Myelodysplastic syndromes ,Clinical Cancer Research ,medicine.disease ,radiology ,Thalidomide ,Hemoglobin ,business - Abstract
Lenalidomide is approved for the treatment of transfusion‐dependent (TD) del(5q) myelodysplastic syndromes (MDS). However, few data are available in patients with transfusion‐independent (TI) del(5q) MDS. In the first, observational, part of this 2‐part study, we assessed the impact of transfusion dependence on overall survival (OS) and non‐leukemic death in untreated del(5q) MDS patients who were TD (n = 136), TI with hemoglobin (Hb) ≥10 mg/dL (n = 88), or TI with Hb
- Published
- 2015
- Full Text
- View/download PDF